Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-04

FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (Advagen Pharma Ltd)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine hydrochloride filed by Advagen Pharma Ltd under the ANDA, authorizing changes to the approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine Hydrochloride (Buprenorphine hydrochloride)

Snippet

SUPPL AP for BUPRENORPHINE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE)